USASOC CY2026 C-sUAS Open Call

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

U.S. Army Special Operations Command (USASOC) is seeking counter-small Unmanned Aircraft Systems (C-sUAS) technologies to protect Army Special Operations Forces (ARSOF) operating in austere, high-risk environments.

Small UAS pose a growing threat through ISR, targeting, and direct attack capabilities. USASOC is looking for TRL 4–7 solutions that improve detection and defeat capabilities while minimizing the electromagnetic signature of the user.

The submission deadline is 01 Dec 2026 : 22:59 GMT-6.

Submissions are currently open and will be accepted beginning 02 Feb 2026 : 23:00 GMT-6 through 01 Dec 2026 : 22:59 GMT-6. If this is aligned with your technology, you should plan to submit before the deadline.

How much funding would I receive?

Typical funding is around $500k - $2m.

What could I use the funding for?

This opportunity supports engagement objectives including:

• Capability Demonstration

• Market Research

• Tech Experimentation

USASOC is specifically interested in C-sUAS technologies that are:

• TRL 4–7

• Handheld or body worn sensors for sUAS detection

• Handheld RF detect and defeat solutions

• GNSS denial or spoofing technologies

• Expeditionary Fixed Sites (EFS) that are man packable <50lbs

• EFS that provide detection capabilities of group 1–3 UAS

All technologies should minimize the electromagnetic signature of the user.

Are there any additional benefits I would receive?

Additional benefits are not specified in the solicitation.

What is the timeline to apply and when would I receive funding?

Open Date: 02 Feb 2026 : 23:00 GMT-6
Deadline: 01 Dec 2026 : 22:59 GMT-6

The deadline to submit is 01 Dec 2026 : 22:59 GMT-6.

Where does this funding come from?

The opportunity is issued by U.S. Army Special Operations Command (USASOC).

Who is eligible to apply?

Eligibility requirements are not specified in the provided solicitation materials.

Entity type restrictions (e.g., small businesses, large businesses, academic institutions, non-profits) are not specified.

What companies and projects are likely to win?

Based on the stated interests, USASOC is seeking technologies that:

• Address sUAS threats to ARSOF

• Fall within TRL 4–7

• Provide handheld, body-worn, RF detect/defeat, GNSS denial/spoofing, or man-packable (<50lbs) Expeditionary Fixed Site capabilities

• Detect group 1–3 UAS

• Minimize the electromagnetic signature of the user

Are there any restrictions I should know about?

Submission requires:

• Uploading a quad chart of your technology (See template)

How long will it take me to prepare an application?

The only required submission material specified is a quad chart of your technology.

Preparation time will depend on how quickly you can complete the required quad chart.

How can BW&CO help?

BW&CO can:

• Assess whether your technology aligns with the stated TRL 4–7 and C-sUAS requirements

• Refine your positioning to clearly address ARSOF operational needs

• Develop and optimize your quad chart to align with USASOC’s stated interests

• Ensure your submission directly reflects the language and priorities in the solicitation

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($4,000) available.

Additional Resources

Review the solicitation here.

CDMRP: FY26 Orthopaedic Research Program (ORP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The FY26 Orthopaedic Research Program (ORP) pre-announcement outlines anticipated funding opportunities supporting innovative, high-impact research to advance treatment and rehabilitation for orthopaedic injuries sustained during combat and service-related activities. This pre-announcement is intended to help teams plan now; it is not a promise of funding. Full Funding Opportunity Announcements (FOAs) with submission deadlines will be posted on Grants.gov and eBRAP when released.

Pre-Application (Preproposal): August 19th

Application: November 18th

How much funding would I receive?

Specific award budgets and totals are not yet provided in the pre-announcement. A sampling of anticipated mechanisms includes:

• Applied Research Award – up to $950,000 total costs over up to 3 years.

• Clinical Research Award (Level 1) – up to $2,000,000 total costs (4-year max).

• Clinical Research Award (Level 2) – up to $3,200,000 total costs (4-year max).
  (Total awards by mechanism and number of awards are not specified at this stage.)

What could I use the funding for?

Projects must address one or more of the FY26 ORP focus areas, including:

• Battlefield fracture-related infection (prevention, early detection, eradication strategies).

• Composite tissue regeneration following high-energy extremity trauma.

• Ligamentous trauma treatments for musculoskeletal soft-tissue instability.

• Limb stabilization and wound protectants enabling prolonged care.

• Osseointegration outcomes for prosthetic limb interfaces.

• Return-to-duty strategies to optimize reintegration and reduce reinjury.

• Military women’s health impacts of orthopaedic care.
  Funding applies to research that improves patient function, restores mobility, and maximizes return to duty in military and service-related contexts.

Are there any additional benefits I would receive?

The pre-announcement does not list additional benefits (e.g., mentoring, training, networking) beyond funding support.

What is the timeline to apply and when would I receive funding?

• Pre-announcement release:February 24, 2026.

• FOAs release: Posted later on Grants.gov and eBRAP (dates not yet specified).

• Pre-Application (Preproposal): August 19th

• Application: November 18th

• Funding start dates: Determined after FOA release and award negotiations (not specified).
  (All deadlines and schedules will be in the final FOAs — not provided in this pre-announcement.)

Where does this funding come from?

Funding is authorized by the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) through the Congressionally Directed Medical Research Programs (CDMRP).

Who is eligible to apply?

Eligibility for each award mechanism will be defined in the full FOAs. From the pre-announcement:

• Independent investigators at all career levels are eligible for many mechanisms, particularly clinical research awards.

• Preproposal required: Some mechanisms require a preproposal through eBRAP, and full application is by invitation only.
  (Complete eligibility details — including institution types, citizenship, and cost share — will be in the FOAs and are not specified here.)

What companies and projects are likely to win?

Specific companies or project profiles most likely to win are not described in the pre-announcement. Competitive applications will align with the ORP focus areas and demonstrate potential to advance orthopaedic care in military and clinical contexts.

Are there any restrictions I should know about?

• The ORP will not consider applications proposing strategies infeasible in battlefield environments for fracture-related infection or tissue regeneration alone.

• The program will not consider biomarker-only research.

• Preproposal submission is required for certain mechanisms; full applications may be by invitation only.

• All submissions must comply with final FOA instructions posted on Grants.gov.

How long will it take me to prepare an application?

With deadlines and FOA details not yet posted, exact preparation time cannot be stated. Given CDMRP’s typical structure, planning should begin now to develop compelling science narratives, compliance documents, and required eBRAP preproposals.

How can BW&CO help?

BW&CO can help you:

• Monitor FOA release dates and mechanism details.

• Translate the final FOA into a targeted application roadmap.

• Develop high-impact narrative, budget, and compliance materials.

• Guide submission strategy on eBRAP and Grants.gov.

• Support preproposal and full application review to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

U.S. Army Futures Command (AFC) Broad Agency Announcement (BAA) - W519TC-25-S-0001

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The U.S. Army Futures Command (AFC), Artificial Intelligence Integration Center (AI2C) has released Broad Agency Announcement W519TC-25-S-0001 for Basic, Applied, and Advanced Scientific Research in artificial intelligence.

This is a continuously open five-year announcement valid throughout the period beginning 01 May 2024 – 31 May 2029, with proposals accepted through 11:59 PM Eastern Daylight Time on 31 MAY 2029.

AI2C is actively seeking white papers and proposals that advance Army-relevant AI technologies across autonomy, AI/ML, decision support, human-AI integration, distributed AI, and related foundational research areas.

Because this BAA is continuously open, companies can submit at any time before 11:59 PM Eastern Daylight Time on 31 MAY 2029, but new start awards are normally obligated early within each fiscal year . Early submission within the fiscal year cycle may improve timing alignment with available funds.

How much funding would I receive?

The solicitation does not specify a minimum or maximum award amount , but most awards range from $500k - $5m

Awards may be made using a variety of instruments, including:

• Procurement contracts

• Grants

• Cooperative agreements

• Technology Investment Agreements (TIAs)

• Other Transactions (OTs)

There is no stated funding cap, award ceiling, or target award size in the BAA.

New start awards are normally obligated early within each fiscal year.

What could I use the funding for?

Funding supports Basic Research, Applied Research, and Advanced Research in AI-related areas.

The BAA defines:

• Basic Research: Systematic study directed toward greater knowledge of fundamental aspects of phenomena without specific application in mind.

• Applied Research: Systematic expansion and application of knowledge to develop useful materials, devices, systems, or methods aligned to recognized Army needs.

• Advanced Research: Development of subsystems and components integrated into prototypes for field experiments or simulated environments, generally at Technology Readiness Levels 4, 5, or 6.

Foundational Research Topics of Interest include:

• Autonomous Platforms

• Artificial Intelligence and Machine Learning Algorithms (AI/ML)

• AI/ML Decision Support

• Human-AI Integration

• Synthetic Environments

• Distributed AI

• Underpinning Methodologies

• Special Topics (posted separately as amendments on SAM.gov)

There are no funding restrictions associated with this BAA.

Are there any additional benefits I would receive?

Depending on the instrument type, benefits may include:

• Potential use of Other Transactions (OTs), which may allow negotiation of expanded intellectual property protections.

• Technology Investment Agreements (TIAs) tailored for commercial firms or research involving commercial application.

• Opportunity for cost sharing, in-kind labor, or facility sharing (optional unless required by instrument type).

• Potential transition into acquisition pathways if research demonstrates military utility.

The BAA also envisions collaboration agreements where no funds are exchanged, such as Cooperative Research and Development Agreements (CRADAs).

What is the timeline to apply and when would I receive funding?

This BAA is a continuously open five-year announcement valid throughout the period beginning 01 May 2024 – 31 May 2029.

Proposals will be accepted through 11:59 PM Eastern Daylight Time on 31 MAY 2029.

New start awards are normally obligated early within each fiscal year.

There is no guaranteed award timeline specified. Award start dates are determined at the time of selection and award notice.

Applicants are encouraged, but not required, to submit a White Paper (limited to three pages) prior to submitting a full proposal.

Where does this funding come from?

Funding is issued by:

• U.S. Army Futures Command (AFC), Artificial Intelligence Integration Center (AI2C)

• Issuing Acquisition Office: U.S. Army Contracting Command – Rock Island Division

The CFDA Number and Title is:

• 12.630 – Basic, Applied, and Advanced Research in Science and Engineering

Awards are issued under statutory authorities including 10 U.S.C. 4001, 10 U.S.C. 4021, and 10 U.S.C. 4022.

Who is eligible to apply?

Eligible applicants include:

• Institutions of higher education

• Non-profit organizations

• For-profit organizations

• Domestic or foreign entities

However:

• Government laboratories

• Federally Funded Research and Development Centers (FFRDCs)

• U.S. Service Academies

are not eligible to participate as prime contractors or recipients .

Foreign organizations and foreign public entities may face security restrictions. Countries on the U.S. State Department List of Countries that Support Terrorism are excluded .

Generally, cost sharing is not required and is not an evaluation factor, except where required by certain instrument types such as OTs or TIAs.

What companies and projects are likely to win?

Proposals are evaluated on:

1. Scientific and Technical Merit (most important factor)

2. Potential Contribution to the Army mission

3. Qualifications and Capabilities of the team and institution

4. Cost (realism, affordability, appropriateness)

5. Past performance

All evaluation factors other than cost, when combined, are significantly more important than cost.

Projects that:

• Demonstrate clear Army relevance

• Advance state-of-the-art AI capabilities

• Show feasibility and potential transition value

• Align directly with identified foundational research topics

are most aligned with stated evaluation criteria.

Are there any restrictions I should know about?

Key restrictions and requirements include:

• No classified submissions .

• Registration in SAM is required prior to award .

• Unique Entity Identifier (UEI/DUNS) required .

• Human Subjects and Animal Use protections apply where relevant .

• Export control (ITAR) compliance may apply to contracts .

• Grants and cooperative agreements are subject to Army Research Risk Assessment Program (ARRP) review for foreign influence risk .

• Proposals must comply with strict formatting limits (e.g., 23-page technical limit) .

Failure to meet submission requirements may result in rejection.

How long will it take me to prepare an application?

The BAA includes a three-stage process:

1. Obtain UEI and register in SAM.

2. Optional White Paper (maximum three pages).

3. Full proposal submission (technical volume + cost volume) .

The technical portion (Abstract, Background, Application Potential, Technical Approach) is limited to 23 pages.

The BAA does not estimate preparation time. Preparation time will depend on:

• Whether you submit a white paper first

• Whether cost documentation (e.g., DCAA-accepted accounting system) is already in place

• Whether you pursue a contract, grant, cooperative agreement, TIA, or OT

For new DoD performers, preparation can be documentation-intensive.

How can BW&CO help?

BW&CO can support:

• Topic alignment to AI2C foundational research areas

• White paper drafting (3-page compliant format)

• Full technical volume development (23-page limit compliance)

• Cost volume structuring aligned with FAR/DFARS requirements

• OT and TIA strategy positioning

• Army relevance framing and transition strategy

• Risk mitigation narrative development

We ensure strict compliance with BAA formatting, eligibility, and evaluation criteria while positioning your technology for maximum Army relevance.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($15,000 + 5%) available.

Additional Resources

Review the solicitation here.

Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The BARDA Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7) is a continuously open funding vehicle supporting advanced R&D of medical countermeasures (MCMs) for CBRN threats, pandemic influenza, and emerging infectious diseases. This is one of the most flexible and recurring federal funding pathways for biotech, diagnostics, and platform companies.

The submission deadline is September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI.

This is not a traditional one-time grant—BARDA accepts submissions on a rolling basis and invites full proposals after an initial screening. Companies with relevant technologies should engage early to maximize alignment and feedback.

How much funding would I receive?

• Not specifically stated, but most awards range between $500k - $5m.

• BARDA states:

  • “Multiple awards of various values are anticipated”

  • Funding depends on:

    • Program priorities

    • Technical merit

    • Fit to Areas of Interest (AOIs)

    • Available funds

What could I use the funding for?

AOI #1: CBRN Vaccines

• 1.1. [SUSPENDED] Needle-Free Technologies to Administer Licensed Vaccines

• 1.2. Sudan Virus and Marburg Virus

  • Advanced development of monovalent vaccines against Sudan virus and Marburg virus

  • Candidate must have:

    • Demonstrated protection from lethal challenge in non-human primate studies

    • Phase 1 clinical safety data

  • Goal includes completion of Phase 2 clinical study(ies) and manufacture of sufficient clinical trial material to support outbreak response

• 1.3. Flexible Vaccine Manufacturing Platform Technologies

  • Antigen production technologies that can:

    • Progress from gene sequence to IND submission in <6 months

    • Be successfully applied to multiple infectious disease targets

    • Scale to >1 million doses

  • Proposals should address at least two CBRN threats, with optional work for additional threats

AOI #2: CBRN Antivirals and Antitoxins

• 2.1. [SUSPENDED] Anthrax Antitoxins

• 2.2. Botulism Antitoxins

  • Next-generation MCMs against botulinum neurotoxins

  • Priority for products with efficacy against serotypes A-G

  • Includes antibody-based products, small molecules, or syndrome-based therapeutics

• 2.3. Smallpox Antivirals

  • Next-generation antiviral therapeutics against smallpox

  • Preference for products with a different class or mechanism than existing FDA-approved smallpox therapeutics

  • Combination therapy potential is preferred

• 2.4. Filovirus Antivirals

  • Therapeutics for Ebolavirus and Marburgvirus

  • Includes:

    • Broad-spectrum antivirals

    • Monoclonal antibodies and related products

    • Syndrome-based therapeutics

    • Post-exposure prophylaxis products

AOI #3: Antimicrobials

• 3.1. MDR Bacteria and Biothreat Pathogens

  • Drug candidates active against biothreat pathogens and/or drug-resistant secondary infections during a CBRN, pandemic influenza, or emerging infectious disease incident

• 3.2. MDR Fungal Infections

  • Broad-spectrum antifungal candidates with novel mechanisms of action

  • Includes Candida species, including Candida auris, drug-resistant Aspergillus species, and rare molds

AOI #4: Radiological/Nuclear Threat Medical Countermeasures

• 4.1. Acute Radiation Syndrome (ARS)

  • Therapeutics for:

    • Thrombocytopenia

    • Pancytopenia

    • Endothelial and vascular injury

    • GI or lung injury

    • Delayed effects of acute radiation exposure

    • Cellular therapies and hematopoietic stem/progenitor cell technologies

• 4.2. Uncontrolled Hemorrhage

  • Blood products and related technologies

  • Therapeutics that replace blood products or extend the resuscitation window

  • Therapies for cellular metabolism and hemostasis dysfunction

• 4.3. Radiation Injury and Trauma Pathophysiologies

  • Biomarker assays

  • Imaging and diagnostic tools

  • Therapeutic solutions targeting injury pathophysiology

• 4.4. Enabling Technologies and Platforms

  • Tissue chips and microphysiological systems

  • Platforms for easier therapeutic use in resource-limited settings

  • Potency assays for cellular therapies and next-generation blood products

• 4.5. [SUSPENDED] Decorporation Agents

AOI #5: Chemical Medical Countermeasures

• 5.1. Pulmonary Agents

  • MCMs to prevent and treat lung damage from agents such as chlorine and phosgene

  • Includes ARDS, pulmonary edema, pulmonary endothelial vascular injury, chemical pneumonitis, reactive airway syndrome, and pulmonary fibrosis

• 5.2. Pharmaceutical-based Agents, including Opioids and Other Respiratory Depressants

  • MCMs for life-threatening overdose from PBAs, respiratory depressants, and/or multi-drug toxicity

  • Threat-agnostic respiratory stimulants are of particular interest

  • Candidates not involving opioid receptor antagonism are prioritized

• 5.3. Vesicants

  • MCMs to ameliorate harmful effects of sulfur mustard and lewisite

  • Preference for drugs that prevent or ameliorate chronic effects

• 5.4. Nerve Agents and Organophosphorus (OP) Pesticides

  • Repurposing or label expansion of already FDA-approved medications

  • Includes treatment of muscarinic, nicotinic, seizure-causing effects, and benzodiazepine-refractory seizures

• 5.5. Knockdown Agents/Cellular Asphyxiants

  • MCMs for cyanides, hydrogen sulfide, phosphine, and related threats

  • Preference for treatments also safe and effective against smoke inhalation-related cyanide exposure

• 5.6. Novel MCM Delivery Mechanisms

  • Improved methods and/or routes of administration for new and existing MCMs

• 5.7. Innovative Approaches to Understanding Chemical Injury in Humans

  • In vitro humanized systems, organoids, organ chips, microphysiological systems, and human-relevant animal models

  • Goal is to identify therapeutic targets and support new treatment development

Under AOI #5, BARDA states that all aspects of advanced clinical stage drug development are permissible for funding, including:

• Nonclinical studies

• Safety

• Toxicology

• PK/PD

• Manufacturing

• Analytical assay development and validation

• Clinical studies, including pediatric studies

• Regulatory submission preparation

• Post-approval requirements

AOI #6: Burn and Blast Medical Countermeasures

• 6.1. Burn and Blast Traumatic Injuries Management

  • Products for full-thickness burns, severe lacerations, penetrating trauma, crush injuries, nerve and vascular trauma

  • Includes enabling technologies such as devices, software, AI-assisted capabilities, pain management, and clinical guidelines

• 6.2. Management of Head Injuries in Trauma

  • Non-invasive or minimally invasive technologies to detect neurotrauma

  • Triage tools for acute traumatic brain injuries

  • Special interest in technologies detecting/localizing internal brain hemorrhage and elevated intracranial pressure/edema

• 6.3. Hemorrhage Control

  • Gels, devices, and other adoptable MCMs for severe hemorrhage from lacerations and junctional wounds

  • Also includes technologies for early detection/localization of internal hemorrhage

• 6.4. [SUSPENDED] Non-Autologous Topical Products to Prevent or Reduce Burn Wound Conversion

• 6.5. Management of Thoracoabdominal Trauma Injuries

  • Detection/diagnosis of internal injuries

  • Portable point-of-care ultrasound and similar technologies

  • Tools to improve management, monitoring, prognosis, and treatment decisions for blunt trauma

• 6.6. Musculoskeletal Injuries

  • Technologies to evaluate, diagnose, triage, and manage traumatic MSK injuries

  • Includes complex fractures, soft tissue injuries, tendons, ligaments, and AI-enabled imaging improvements

• 6.7. [SUSPENDED] Special Instruction for Health Economic Impact Assessment of Burn MCMs

• 6.8. Platform Agnostic Software for AI Augmentation of Ultrasound Imaging Data

  • Software connecting ultrasound devices with minimal API development

  • AI/ML support for EMS and ED triage

  • Product should seek FDA clearance as required

AOI #7: Diagnostics

BARDA divides diagnostics into four threat areas:

• 7.1. Biothreats

• 7.2. Antibiotic resistance

• 7.3. Pandemic influenza

• 7.4. Threat-agnostic diagnostics

Subpoints:

7.1. Biothreat Agent Diagnostics

• 7.1.1. Biothreat Agent Diagnostics: Point-of-Care

  • Rapid point-of-care diagnostic systems for listed biothreats

  • TRL 4 or greater required

• 7.1.2. Biothreat Agent Diagnostics: Laboratory

  • Automated laboratory assays for listed biothreats

  • Single-threat and multiplex assays will be considered

  • TRL 4 or greater required

• 7.1.3. Biothreat Agent Diagnostics: Filovirus Point-of-Care and Remote Settings

  • Rapid, accurate, CLIA-waivable, field-useable molecular diagnostics for filoviruses

  • Must at minimum detect Ebola virus, Sudan virus, Bundibugyo virus, Taï Forest virus, and Marburg virus

  • TRL 3 or greater, with expectation of advancing to TRL 4 and regulatory submission

7.2. Antibiotic Resistance Diagnostics for Priority Bacterial Pathogens

• 7.2.1. Bacterial Antimicrobial Resistance (AMR) Testing Direct from Specimen

  • Rapid ID and AMR testing from primary clinical specimens

  • Broad pathogen coverage

  • TRL 4 or greater required

• 7.2.2. [SUSPENDED] Bacterial vs. Viral Infections: Point-of-Care

• 7.2.3. AMR Sequencing Solutions

  • Sample-to-answer sequencing solutions for identifying pathogens with known and/or novel resistance determinants

  • TRL 4 or greater required

7.3. Influenza Diagnostics

• 7.3.1. Influenza Testing in an OTC and CLIA-waived environment

  • Molecular or high-sensitivity antigen tests for influenza A and B

  • Point-of-care and home-use

  • TRL 4 or greater required

• 7.3.2. [SUSPENDED] Pan-Influenza Diagnostics: Point-of-Care or Laboratory

• 7.3.3. [SUSPENDED] Point-of-Care Multiplex Assay for Detection of Influenza Virus

7.4. Threat-Agnostic Diagnostics

• 7.4.1. Metagenomic Next-Generation Sequencing (mNGS)-Based Diagnostic for Viral and Bacterial Pathogens

  • Advanced development, clinical evaluation, and FDA clearance of mNGS-based assays

  • Laboratory and point-of-care tests are sought

  • TRL 4 or greater required

AOI #8: IEID Vaccines

• 8.1. Advanced Development of Faster or More Effective Vaccines

  • 8.1.1. Faster Vaccines

    • Licensed, domestically manufactured vaccines with goals of:

      • 100 days from sequence availability to release of first doses

      • 130 days from sequence availability to doses sufficient to immunize the U.S. and global population

  • 8.1.2. More Effective Vaccines

    • Products or formulations such as adjuvants or other technologies that:

      • Elicit a priming and protective response in immunologically naïve recipients with a single dose

      • Improve stability, sustainability, and/or utility of stockpiled vaccines

  • 8.1.3. Clinical trials to expand the age range on the label of currently licensed vaccines

• 8.2. Innovative Vaccine Product and Production Enhancements

  • 8.2.1. Platform technologies

  • 8.2.2. Manufacturing

  • 8.2.3. Assays for product release

  • 8.2.4. Administration

AOI #9: IEID Therapeutics

• 9.1. Broad Spectrum Antiviral Therapeutics for Influenza

  • New broad-spectrum direct- or indirect-acting antivirals for respiratory viral infections including influenza in outpatient settings

• 9.2. Immune Modulators or Therapeutics Promoting Lung Repair

  • Therapeutics to prevent, treat, and/or improve outcomes of ARDS caused by pandemic or seasonal influenza and other respiratory infections

• 9.3. Pre-exposure Prophylaxis – Influenza

  • Antivirals for pandemic preparedness and for people with inadequate influenza vaccine response

  • Preference for long-acting products providing at least one month of protection from a single dose

• 9.4. [SUSPENDED] COVID-19 Monoclonal Antibody Therapeutics for Treatment

AOI #10: ImmuneChip+

BARDA seeks advanced microphysiological systems and tissue-chip technologies.

Offerors should address two or more of these five components:

• 1) Infection with a relevant pathogen, insult with toxins/toxicants, exposure to acute ionizing radiation, or exposure to chemical agents

• 2) Integration of at least two different tissues in addition to immune component(s)

• 3) Near-continuous monitoring of the MPS for at least two weeks

• 4) Semi-automated or automated manufacturing of the device

• 5) Biological characterization of the MPS and recapitulation of existing clinical data in response to injury/morbidity and various MCMs

BARDA also explicitly encourages proposals in these topic areas:

• Development of modular multi-tissue systems

• Characterization studies on known approved and unapproved therapeutic candidates

• Natural history studies of acute radiation syndrome in target organ systems

• Natural history studies in animal chip models

• Vascularized models with endothelial cells that can model vascular injury

AOI #11: [SUSPENDED] COVID-19 Immune Assay(s) Development and Implementation

AOI #12: Flexible and Strategic Therapeutics (FASTx)

BARDA seeks adaptable antiviral platforms.

Required elements in Market Research Abstract and Proposal submissions:

• Preliminary platform data demonstrating in vitro efficacy of a candidate against filoviruses

• Proposal to develop and advance candidates against two unique targets:

  • 1 filovirus

  • 1 “to be determined” HHS priority threat

• Identification of technical gaps/challenges, such as:

  • Formulation

  • Manufacturability

  • Safety and toxicity

  • Delivery to target tissues

  • Pharmacokinetics

  • Efficacy

• Justification of how common aspects of the platform can accelerate regulatory review of later products

Additional guidance:

• Therapeutic indications are preferred

• Post-exposure prophylaxis will only be considered for filovirus targets

• For this AOI, BARDA states that potential offerors must request a pre-submission call before submitting an MRA

• MRAs must be received by April 24, 2026 for consideration of an award in the 2026 fiscal year

Are there any additional benefits I would receive?

Yes. BARDA provides non-dilutive capital plus strategic support, including:

• Access to:

  • Animal study networks

  • Flexible manufacturing facilities

  • Regulatory and clinical expertise

• Potential progression through:

  • FDA approval, licensure, or clearance

• Engagement with:

  • BARDA experts

  • Interagency partners (PHEMCE)

What is the timeline to apply and when would I receive funding?

Submission deadline:

• September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI.

Process (3 stages):

1. Stage 1 – Pre-submission call (optional)

   • Can occur anytime

   • Response within ~1 week

2. Stage 2 – Quad Chart + Market Research Abstract

   • Submit anytime before September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI

   • BARDA response: within 120 days

3. Stage 3 – Full Proposal (by invitation or direct submission)

   • Deadline: September 25, 2028, at 4:30pm Eastern Time, unless otherwise indicated in an AOI

   • Response: within 120 days

Where does this funding come from?

• U.S. Department of Health and Human Services (HHS)

• Administration for Strategic Preparedness and Response (ASPR)

• Biomedical Advanced Research and Development Authority (BARDA)

Authorized under:

• Federal Acquisition Regulation (FAR)

• Pandemic and All-Hazards Preparedness legislation

Who is eligible to apply?

• Open to ALL responsible sources, including:

  • Private companies

  • Startups

  • Academic institutions

  • Government labs

  • Teams/consortia

Requirements:

• Must be registered in SAM.gov

Special cases:

• FFRDCs and government entities must justify eligibility

Encouraged participants:

• Small businesses

• Women-, minority-, veteran-owned firms

• HBCUs and other underserved institutions

What companies and projects are likely to win?

BARDA prioritizes:

Strong alignment with AOIs, including:

• Vaccines, therapeutics, diagnostics, and platforms for:

  • CBRN threats

  • Pandemic influenza

  • Emerging infectious diseases

High-performing proposals typically have:

• Advanced development stage (clear TRL justification)

• Strong technical and clinical data

• Clear FDA regulatory pathway

• Scalable manufacturing plan

• Commercial viability and sustainability

Evaluation criteria (in order):

1. Program relevance

2. Scientific and technical merit

3. Team capabilities and experience

Are there any restrictions I should know about?

Key restrictions include:

• No gain-of-function research

• All submissions must be unclassified

• Must comply with:

  • FDA regulations (GCP, GMP, GLP)

  • Export control laws

• Proposals must follow strict formatting and submission rules

• Costs to prepare proposals are not reimbursable

How long will it take me to prepare an application?

• Stage 2 (Quad Chart + Abstract):

  • Relatively lightweight (≤14 pages total)

• Stage 3 (Full Proposal):

  • Highly detailed and complex (up to ~120+ pages)

  • Includes:

    • Technical proposal

    • Cost proposal

    • Regulatory, manufacturing, and clinical plans

Estimated effort:

• Not specified in the solicitation

How can BW&CO help?

BW&CO can support you across all three BARDA stages:

• AOI targeting and fit assessment

• Stage 1 strategy and positioning

• Quad Chart + Market Research Abstract development

• Full proposal writing (technical + cost volumes)

• Regulatory and commercialization narrative alignment

• Review and red-teaming for BARDA evaluation criteria

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

H92240-26-S-C001 Naval Special Warfare Command Commercial Solutions Opening (CSO)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Naval Special Warfare Command (NSWC) has released Commercial Solutions Opening (CSO) H92240-26-S-C001 to rapidly acquire innovative unmanned systems (UxS) capabilities for Special Operations Forces (SOF).

NSWC intends to award FAR-based Firm-Fixed-Price contracts and/or Other Transaction (OT) Agreements under 10 U.S.C. §§ 4021–23 to support:

• “UxS as a Service” subscription-based solutions

• First Person View (FPV) ISR operations

• FPV Kinetic operations

This is a multi-phase competitive process running throughout 2026/2027.

Deadlines:

• AOI 1 submissions are due 25 January 2026.

• AOI 2 and AOI 3 submissions are due 9 January 2026, 9 April 2026, 9 July 2026, and 9 October 2026.

If you have a deployable UxS platform, FPV ISR capability, or FPV kinetic solution with strong production readiness and compliance posture, this is an active acquisition pathway—not just research funding. Early submission increases the likelihood of engagement and Phase II selection.

How much funding would I receive?

The solicitation does not specify award amounts, funding ceilings, number of awards, or total program value.

Awards may be made as:

• FAR Part 12 Firm-Fixed-Price contracts

• Other Transaction (OT) Agreements under 10 U.S.C. 4022–23

Multiple awards may be made if solutions meet technical criteria and funds are available.

If an OT Prototype Project is awarded, there is potential for a noncompetitive follow-on production agreement under 10 U.S.C. 4022(f), subject to successful prototype completion.

What could I use the funding for?

Funding is intended to deliver operational unmanned system capabilities to NSWC and SOF operators.

AOI 1: “UxS as a Service”

Subscription-based models providing:

• Complete UxS systems

• Platforms and payloads

• Communications and data transfer equipment

• Software, AI, PED systems

• Command and Control (C2) software and AI

• Launch/recovery systems

• Attachments and modular components

• Updates, upgrades, training, maintenance, and spare parts

Offerors must clearly define:

• Number of systems available

• Delivery speed and replenishment rate

• Interoperability with C2 systems

• Modular Open Systems Approach compliance

• Regulatory and compliance posture

AOI 2: FPV ISR Operations

Solutions that improve individual operator situational awareness using FPV systems capable of:

• Locating, identifying, and reporting targets

• Multi-mission ISR configurations

• Advanced ease-of-use and operational capability

AOI 3: FPV Kinetic Operations

FPV systems that enable operators to kinetically engage targets, including:

• Configurable ISR/kinetic capability

• Payload flexibility

• Advanced control modes

Technical characteristics of interest include:

• 0m–50K operational distance

• 45–60 minute duration

• Autonomous capability

• Swarm and saturation capability

• GNSS resilience

• EMI resilience

• Maritime launch capability

• Waterproof ISR sUAS sub-surface launch

• Modular payload integration

• Ability to supply at least three (3) prototypes (if applicable)

The period of performance should generally be no greater than 12 months unless otherwise negotiated.

Are there any additional benefits I would receive?

This CSO offers:

• Direct access to NSWC and USSOCOM experimentation venues

• Potential collaborative Statement of Work development

• Eligibility for OT prototype awards

• Potential follow-on noncompetitive production agreements

• Possible external Venture Capital interest from strategic Government partners

Solutions are treated as commercial items under DFARS 212.70.

What is the timeline to apply and when would I receive funding?

Phase I – Solution Brief (White Paper / Scout Card)

Submit via Vulcan.

Deadlines:

• AOI 1: 25 January 2026

• AOI 2 & AOI 3: 9 January 2026, 9 April 2026, 9 July 2026, 9 October 2026

Government aims to provide:

• Phase I evaluation response within 45 days after submission

• Phase II evaluation notification within 30 calendar days of the demonstration/experimentation

Phase II – Demonstration / Pitch

• Conducted at NSWC or USSOCOM venues

• At offeror’s expense

• Must provide ROM pricing and schedule

• May require at least three (3) operational units and two (2) trained operators

Phase III – Proposal

• Invitation-only

• Collaborative SOW development

• Contract/OT negotiation

The solicitation does not specify award issuance timing beyond these evaluation targets.

Where does this funding come from?

Funding comes from:

• Naval Special Warfare Command (NSWC)

• United States Special Operations Command (USSOCOM)

• Department of War (DoW) (as referenced in the solicitation)

Awards are made under:

• FAR Part 12

• 10 U.S.C. §§ 4021–23 (Other Transaction Authority)

Who is eligible to apply?

Eligible applicants include:

• Traditional defense contractors

• Non-traditional defense contractors (as defined in 10 U.S.C. 2302(9))

• Foreign-owned businesses (independently or via teaming with U.S.-owned businesses)

Requirements:

• Registration in SAM.gov

• Registration in WAWF for invoicing

• Ability to meet export control requirements (if applicable)

• All Phase I submissions must be unclassified

Note: Some Phase II discussions may require personnel clearances depending on venue.

What companies and projects are likely to win?

Solutions will be evaluated individually based on:

Technical

• Merit and feasibility

• Relevance to AOI

• Ability to address vulnerabilities

• Innovation (as defined under DFARS 212.7001)

Importance to Agency Programs

• Operational relevance

• Business viability

• Commercial viability

Affordability

• Price and budgetary considerations

Strong candidates will demonstrate:

• Production readiness

• Supply chain transparency

• Compliance with NDAA and regulatory requirements

• Modular, interoperable architectures

• Clear operational utility to SOF

The Government reserves the right to move directly to award without demonstration.

Are there any restrictions I should know about?

• Phase II participation is at the offeror’s expense.

• Costs of preparing submissions are not reimbursed.

• Technical data may require export approvals.

• Compliance may include:

  • NDAA compliance

  • Remote ID

  • FAA/ICAO/DoW compliance

  • Cybersecurity

  • Insurance/liability

• Submissions must not exceed five (5) pages for Phase I Solution Brief (12-point font).

• Only a warranted Contracting or Agreements Officer can obligate the Government.

How long will it take me to prepare an application?

Phase I submission requirements:

• Maximum five (5) pages

• 12-point font

• Concise, substantive response

• Technical and business overview

• Capability differentiators

• Readiness timeline

• Rough Order of Magnitude schedule and budget

For companies with a mature UxS product and clear business model, preparation time is typically measured in weeks rather than months.

How can BW&CO help?

BW&CO can:

• Position your UxS or FPV capability against the correct AOI

• Refine your five-page Solution Brief to align with NSWC evaluation criteria

• Strengthen innovation framing under DFARS 212.7001

• Develop ROM pricing strategy

• Prepare you for Phase II demonstration requirements

• Support OT negotiation strategy and Phase III proposal development

This is an operational acquisition pathway. Positioning and clarity matter.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

OUSW-R&E/P&E Joint Rapid Fielding Activity

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

One Nation Innovation, in coordination with the Joint Rapid Fielding Activity (JRFA), is seeking qualified vendors to deliver prototype organizational, technical, and operational support services to accelerate emerging warfighting capabilities from prototyping through fielding to the Joint Force .

This opportunity focuses on building a scalable program management and technical support framework that enables rapid prototyping, experimentation, assessment, and transition of technologies aligned with Department of War (DoW) modernization and rapid capability development priorities .

The solicitation does not specify an application deadline.

If your firm can operate in classified environments, manage complex technical integrations, and accelerate technology transition at speed, this is a strategically positioned prototype opportunity with potential follow-on production or scaling awards.

How much funding would I receive?

It states that:

• This prototype will be awarded leveraging the One Nation Innovation Other Transactional Agreement (OTA) vehicle .

• The initial award may be augmented with additional prototype or production awards pending successful evaluation, operational fit, and government need .

• Multiple awards may be made based on technical merit, readiness, and mission alignment .

A Rough Order of Magnitude (ROM) cost estimate is required as part of the proposal .

What could I use the funding for?

Funding supports delivery of integrated organizational, technical, and operational support services to JRFA .

Activities may include:

• Disciplined program management and mission-engineering–informed planning

• Technology identification, maturation planning, and documentation

• Development of feasibility refinements, requirements clarification, and risk identification artifacts

• Preparation of technologies for operationally relevant testing, including safety, RMF, spectrum, airworthiness, logistics, and operator-facing materials

• Support for prototyping and experimentation events (planning, synchronization, data collection, troubleshooting, coordination)

• Integration risk identification and interoperability gap resolution

• Knowledge management systems, templates, taxonomies, and digital collaboration environments

• Outreach support to grow and nurture the defense industrial and innovation ecosystem

• Support for innovation burden sharing and experimentation with allies and security partners

Expected deliverables include:

• Monthly status reports

• Planning, maturation, and evaluation artifacts

• Readiness and integration materials

• Knowledge-management tools and repeatable processes

• Final report with metrics, lessons learned, and transition recommendations

• Other deliverables as required by the JRFA mission owner

Are there any additional benefits I would receive?

The solicitation states:

• The initial award may be augmented with additional prototype or production awards pending successful evaluation, operational fit, and government need .

• Successful solutions and prototypes may transition to follow-on task orders or scaling activities .

This creates a potential pathway beyond the initial prototype effort.

What is the timeline to apply and when would I receive funding?

This is an Open Challenge.

• Submissions remain open for extended durations.

• Submissions are generally reviewed biweekly.

• There is no specified application deadline in the solicitation.

The solicitation does not specify a defined award decision timeline or funding disbursement schedule.

Offerors must include a Schedule outlining prototype delivery, deployment, and phased demonstration.

Where does this funding come from?

Awards will be made leveraging the One Nation Innovation Other Transactional Agreement (OTA) vehicle.

One Nation Innovation is a 501(c)(3) nonprofit intermediary for rapid government acquisition and innovation.

Who is eligible to apply?

The solicitation does not explicitly define eligibility restrictions.

Proposals must include:

• Organization name

• Lead point of contact

• Contact information

Proposals must also address readiness for classified work and ability to operate within government-managed prototype environments.

No additional eligibility limitations are specified in the solicitation.

What companies and projects are likely to win?

Based on the stated evaluation priorities, competitive applicants will demonstrate:

• Ability to mature technologies in pre-requirement environments aligned with DoW priorities

• Demonstrated skill in structured prototyping, experimentation planning, and data collection

• Capacity to produce test-readiness artifacts (safety, certification, interoperability, logistics) at speed and rigor

• Strength in generating bodies of evidence from technical and operational data

• Capability to field a stable, high-competence, cross-functional team that can manage complexity and resolve integration challenges rapidly

Past performance demonstrating rapid deployment or technical advisory support in DoD or dual-use adjacent environments is required .

Are there any restrictions I should know about?

• Proposal length is limited to 10 pages (12pt Arial font).

• A separate cover page is required.

• Required proposal sections are explicitly defined (Technical Overview, Integration Path, ROM Cost Estimate, Past Performance, Schedule, Proposed Personnel Outline).

• Solutions must meet defined mechanical, operational, safety, environmental, and integration criteria.

• Security Requirements: None.

No cost share requirement is specified.

No defined funding cap is specified.

How long will it take me to prepare an application?

The solicitation does not specify preparation timelines. However, the required 10-page proposal must include:

• Technical approach

• Integration readiness

• ROM cost estimate

• Relevant past performance

• Delivery schedule

• Personnel outline

For teams with an existing launcher solution or prototype, preparation time may be shorter. For earlier-stage concepts requiring detailed integration and cost modeling, preparation may require additional internal coordination.

How can BW&CO help?

BW&CO can:

• Translate this JRFA Support challenge into a tightly aligned, evaluator-focused 10-page proposal

• Position your firm against the stated evaluation priorities

• Structure your technical narrative around rapid maturation, experimentation readiness, and transition acceleration

• Develop a compliant ROM cost estimate narrative

• Package past performance to directly address rapid deployment and advisory credibility

• Ensure security positioning is clearly articulated up to TOP SECRET requirements

This is a rolling, biweekly review opportunity. Speed and clarity matter.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

OUSW-R&E/PE Unmanned Aerial System (UAS) Launcher Challenge

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The OUSW-R&E/PE Unmanned Aerial System (UAS) Launcher Challenge is an open, rolling prototype opportunity seeking solutions to design and develop a launcher system capable of reliably, safely, and efficiently deploying Group 2–3 UAS platforms.

This is an Open Challenge, meaning submissions remain open for extended durations and are reviewed biweekly. There is no specified application deadline in the solicitation.

Multiple awards may be made. Successful prototypes may transition to follow-on task orders or scaled production. If you have a modular, portable, and field-ready launcher system that meets mechanical, operational, and safety requirements outlined in the Challenge, this is a live pathway into government prototype and potential production work.

How much funding would I receive?

The solicitation does not specify a defined award amount, ceiling, or funding range.

Key funding notes:

• Awards will be made under the One Nation Innovation Other Transactional Agreement (OTA) vehicle.

• The initial award may be augmented with additional prototype or production awards pending successful testing and government need.

• Multiple awards may be made.

Offerors must provide a ROM Cost Estimate covering prototype execution, integration, and optional production.

What could I use the funding for?

Funding supports development and demonstration of a UAS launcher prototype that meets the Challenge objectives.

The launcher must:

Mechanical Requirements

• Withstand repeated launches and environmental stresses

• Allow angle and direction modifications

• Be portable and field-deployable

• Deliver sufficient launch force without damaging the UAS

Operational Requirements

• Enable rapid setup and tear-down

• Include intuitive controls

• Operate on battery, generator, or manual power with backup options

• Function in wind, rain, and temperature extremes

Safety Requirements

• Prevent accidental launches

• Protect operators and UAS

• Include an emergency stop or abort feature

• Adhere to relevant safety standards and regulations

Environmental and Maintenance Requirements

• Use corrosion-resistant materials

• Be easy to inspect and maintain

• Minimize noise and environmental impact

Integration and Future-Proofing

• Integrate with ground control stations and telemetry systems

• Allow software and hardware upgrades

• Include data logging capability

Are there any additional benefits I would receive?

Beyond the initial prototype award:

• Potential for additional prototype or production awards

• Opportunity to transition to follow-on task orders or scaled production

• Engagement through the One Nation Innovation OTA vehicle, designed for rapid government acquisition

What is the timeline to apply and when would I receive funding?

This is an Open Challenge.

• Submissions remain open for extended durations.

• Submissions are generally reviewed biweekly.

• There is no specified application deadline in the solicitation.

The solicitation does not specify a defined award decision timeline or funding disbursement schedule.

Offerors must include a Schedule outlining prototype delivery, deployment, and phased demonstration.

Where does this funding come from?

Awards will be made leveraging the One Nation Innovation Other Transactional Agreement (OTA) vehicle.

One Nation Innovation is a 501(c)(3) nonprofit intermediary for rapid government acquisition and innovation.

Who is eligible to apply?

The solicitation does not explicitly define eligibility restrictions.

Proposals must include:

• Organization name

• Lead point of contact

• Contact information

Proposals must also address readiness for classified work and ability to operate within government-managed prototype environments.

No additional eligibility limitations are specified in the solicitation.

What companies and projects are likely to win?

Awards may be made based on:

• Technical merit

• Delivery readiness

• Mission alignment

Competitive solutions will demonstrate:

• Ability to accommodate Group 2–3 UAS platforms

• Modular, portable design

• Compliance with mechanical, operational, safety, environmental, and integration requirements

• Readiness for integration into government-managed prototype environments

Past performance from DoD or dual-use adjacent work demonstrating rapid deployment or technical advisory support is required.

Are there any restrictions I should know about?

• Proposal length is limited to 10 pages (12pt Arial font).

• A separate cover page is required.

• Required proposal sections are explicitly defined (Technical Overview, Integration Path, ROM Cost Estimate, Past Performance, Schedule, Proposed Personnel Outline).

• Solutions must meet defined mechanical, operational, safety, environmental, and integration criteria.

• Security Requirements: None.

No cost share requirement is specified.

No defined funding cap is specified.

How long will it take me to prepare an application?

The solicitation does not specify preparation timelines. However, the required 10-page proposal must include:

• Technical approach

• Integration readiness

• ROM cost estimate

• Relevant past performance

• Delivery schedule

• Personnel outline

For teams with an existing launcher solution or prototype, preparation time may be shorter. For earlier-stage concepts requiring detailed integration and cost modeling, preparation may require additional internal coordination.

How can BW&CO help?

BW&CO can:

• Translate your existing launcher technology into a government-aligned Technical Overview

• Position your solution against the stated mechanical, operational, and safety criteria

• Structure your Integration Path for prototype environment readiness

• Develop a defensible ROM Cost Estimate narrative

• Highlight relevant DoD or dual-use past performance

• Ensure strict compliance with page limits and required sections

This is a rolling, biweekly review opportunity. Speed and clarity matter.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Vision Research Program (VRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Urgent Opportunity: The Vision Research Program (VRP) has released a pre-announcement for FY26 anticipated funding opportunities as part of the Congressionally Directed Medical Research Programs. These pre-announcements are meant to help investigators plan now — full funding opportunity announcements (FOAs) with deadlines will be posted soon on Grants.gov.

Key Opportunity: Prepare your research ideas targeting military exposure-related visual injury and treatment now — this program will fund high-impact research that advances understanding, diagnosis, treatment, stabilization, and restoration of vision after combat and operational injuries.

Pre-Applications are due on 7/28/26 and 8/25/26.

Full Applications are due on 9/10/26 and 11/12/26.

How much funding would I receive?

The pre-announcement does not specify total program funding.

Funding by mechanism in the anticipated FOA (for individual awards):

• Clinical Trial Award: up to approximately $2.6M total costs (max 3 years)

• Investigator-Initiated Research Award:

  • Funding Level 1: up to $400,000 total costs (max 2 years)

  • Funding Level 2: up to $1.2M total costs (max 3 years)

• Translational Research Award: up to $1.6M total costs (max 3 years)

• Mentored Clinical Research Award: up to $75,000 total costs (max 1.5 years)

What could I use the funding for?

Funding will support:

• Understanding and treating eye injury or visual dysfunction caused by military exposures.

• Improving diagnosis, stabilization, and treatment of eye injuries in austere and prolonged care environments.

• Restoring visual function after military exposure-related vision loss or severe impairment.

Specific allowable uses will be detailed in the full FOA.

Are there any additional benefits I would receive?

• Being part of a CDMRP-managed research portfolio with a history of high-impact biomedical awards.

• Two-tier review that evaluates both scientific quality and programmatic relevance (once FOA is published).

What is the timeline to apply and when would I receive funding?

• Pre-Applications are due on 7/28/26 and 8/25/26.

• Full Applications are due on 9/10/26 and 11/12/26.

Where does this funding come from?

Funding is provided by the FY26 Defense Appropriations Act, as part of the Congressionally Directed Medical Research Programs (CDMRP) managed by the Defense Health Agency Research and Development / Medical Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

Eligibility requirements will be defined in the full FOA, not in this pre-announcement.

What companies and projects are likely to win?

Programs with strong relevance to combat and operational vision injury.

1. Projects aligned with diagnosis, acute care stabilization, and visual function restoration.

2. Investigators with evidence of clinical relevance and translational potential.

Are there any restrictions I should know about?

• The pre-announcement is not a promise or obligation for awards.

• Applicants must wait for the full FOA to understand eligibility, submission requirements, and restrictions.

How long will it take me to prepare an application?

Planning should begin now, as the pre-announcement is intended to give time for idea development.

How can BW&CO help?

BW&CO can:

• Translate the full FOA into CEO-ready website copy once published.

• Map your project to the right mechanisms (e.g., clinical vs. translational).

• Prepare submission strategy, narrative, and budget.

• Support compliance with CDMRP requirements and two-tier review expectations.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Melanoma Research Program (MRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Congressionally Directed Medical Research Programs (CDMRP) released a pre-announcement for anticipated FY26 Melanoma Research Program (MRP) funding opportunities. This notice signals that new award mechanisms and funding will be forthcoming, but the application deadlines are not yet specified; they will be published in the formal Funding Opportunity Announcement (FOA) on Grants.gov and eBRAP once available.

How much funding would I receive?

• Idea Award: Maximum total costs up to $560,000 (period up to 2 years).

• Melanoma Academy Scholar Award: Maximum total costs up to $770,000 (period up to 3 years).

• Team Science Award: Maximum total costs up to $2.1 million (period up to 3 years).

• Focused Program Award – Rare Melanomas: Maximum total costs up to $2.8 million (period up to 4 years).

• Survivorship Research Award: Maximum total costs up to $1.015 million (period up to 3 years).

What could I use the funding for?

• All awards must address one or more of the FY26 MRP focus areas:

  • Identify, understand, and mitigate melanoma risk factors and develop biomarkers.

  • Develop detection/diagnosis technologies that improve risk stratification.

  • Define mechanisms of initiation, response/resistance to therapy, progression, recurrence, metastasis.

  • Develop new preclinical models representing disease evolution (cutaneous and rare subtypes).

  • Address unmet needs across cancer research spectrum for rare melanomas.

  • Address psychological/social impacts, quality of life, treatment toxicities, and survivorship issues.

Are there any additional benefits I would receive?

• Melanoma Academy Scholar Award includes mentoring, national networking, and structured career support.

What is the timeline to apply and when would I receive funding?

• The pre-announcement is available now (released February 18, 2026); full FOAs will be released later on Grants.gov.

• Exact pre-application and application deadlines will be specified in those FOAs—not yet provided in the pre-announcement.

• Funding start dates will depend on the FOA timeline and award negotiations—not specified in the pre-announcement.

Where does this funding come from?

Funding is provided through the FY26 Defense Appropriations Act and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (MRDC) under the CDMRP.

Who is eligible to apply?

Eligibility for each award mechanism is defined in the full FOA. From the pre-announcement:

• Idea Award: Investigators at or above the postdoctoral level (or equivalent).

• Melanoma Academy Scholar Award: Investigators within 7 years of first faculty appointment.

• Team Science Award: Independent investigators (Assistant Professor level or equivalent).

• Focused Program Award – Rare Melanomas: Initiating PI at Associate Professor level or equivalent; Partnering PIs at Assistant Professor level or above.

• Survivorship Research Award: Independent investigators (Assistant Professor level or equivalent).

Detailed eligibility criteria (organization types, citizenship, cost share, etc.) will be in the FOA—not specified in the pre-announcement.

What companies and projects are likely to win?

Not specified in the pre-announcement; CDMRP typically funds high-risk, high-gain research that aligns tightly with the listed focus areas and relevance to melanoma biology, detection, survivorship, and unmet clinical needs. Projects that integrate multidisciplinary approaches or include military/VA relevance are typically competitive, but the solicitation does not provide explicit criteria.

Are there any restrictions I should know about?

• The pre-announcement states that submission does not guarantee FOAs or funding.

• All applications must adhere to the final FOA instructions on Grants.gov when released.

• Preliminary data expectations, animal or human subjects requirements, and allowable costs will be defined in the FOA—not yet specified here.

How long will it take me to prepare an application?

• Not specified in the pre-announcement because deadlines are not yet posted. Generally, planning should begin now given the complexity of CDMRP submissions and required pre-applications (e.g., eBRAP).

How can BW&CO help?

BW&CO can:

• Monitor the release of the official FOA and deadlines.

• Translate the FOA into a targeted application strategy.

• Help craft compelling project narrative, budget, and compliance sections.

• Provide review, editing, and submission support to maximize competitiveness.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Spinal Cord Injury Research Program (SCIRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

On February 17, 2026, the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) released the Spinal Cord Injury Research Program (SCIRP) anticipated funding opportunities for Fiscal Year 2026 (FY26), providing researchers with key priorities and award mechanisms to plan applications ahead of full Funding Opportunity Announcements. This pre-announcement outlines the SCIRP’s research goals and award structures, including a strong emphasis on clinical, translational, and investigator-initiated research in spinal cord injury.

Pre-Applications are due on 08/03.

Full-Applications are due on 11/12.

How much funding would I receive?

The pre-announcement specifies award maximums for each mechanism (total costs, including direct and indirect):

• Clinical Trial Award

  • Single PI: up to $4.8M over 4 years

  • Early-Career Partnership Option: up to $4.96M over 4 years

• Clinical Translation Research Award

  • Single PI: up to $2.0M over 3 years

  • Early-Career Partnership: up to $2.16M over 3 years

• Translational Research Award

  • Single PI: up to $2.0M over 3 years

  • Early-Career Partnership: up to $2.16M over 3 years

• Investigator-Initiated Research Award

  • Single PI: up to $800,000 over 3 years

  • Early-Career Partnership: up to $960,000 over 3 years

What could I use the funding for?

Funding supports research that advances spinal cord injury (SCI) understanding, treatment, and care across four major areas:

• Acute Injury Intervention

  • Develop and test interventions to protect spinal cord tissue after injury with measurable neurological benefit.

• Secondary Health Effects

  • Research interventions addressing long-term consequences of SCI across the lifespan.

• Psychosocial Issues

  • Test strategies for promoting psychosocial well-being tailored to people with SCI and their families/care partners.

• Rehabilitation and Regeneration

  • Advance rehabilitation strategies and regenerative/neuroplastic approaches for improved functional recovery.

Are there any additional benefits I would receive?

FY26 SCIRP includes an Early-Career Partnership Option across all award mechanisms, designed to:

• Encourage collaboration between established and emerging investigators.

• Provide two individual awards under a single project with separate budgets.

• Support career development while increasing research capacity.

What is the timeline to apply and when would I receive funding?

Pre-Applications are due on 08/03.

Full-Applications are due on 11/12.

Where does this funding come from?

SCIRP is part of the CDMRP, a Department of Defense research portfolio funded through the Defense Appropriations Act. For FY26, the CDMRP received appropriations to fund 34 research programs including SCIRP.

Who is eligible to apply?

Eligibility varies by award mechanism, but in general:

• Independent investigators at all career levels are eligible for single PI awards.

• Early-Career Partnership Option requires one early-career investigator meeting defined experience criteria.

Specific eligibility criteria and organizational requirements will be detailed in the FOAs. al relevance.

What companies and projects are likely to win?

Projects most competitive will:

• Directly address one or more SCIRP priority research areas.

• Demonstrate scientific impact, innovation, and relevance to SCI outcomes.

• Include clear paths to clinical or translational impact (as specified by mechanism).

• (For Early-Career Partnership) show strong mentorship and collaborative planning.

Are there any restrictions I should know about?

• Pre-applications are required before full applications.

• All research must conform to final FOA requirements once released.

• Funding opportunity terms, budgets, eligible costs, and indirect cost policies will be specified in FOAs.

How long will it take me to prepare an application?

Preparation time depends on research maturity and team readiness, but investigators should factor in:

• Time to align research with SCIRP priorities.

• Drafting a competitive pre-application (often weeks before FOA deadlines).

• Preparing full application (including budgets, human subjects, partnerships).
  (SCIRP pre-announcement is intended to give applicants advance planning time.)

How can BW&CO help?

If you need assistance with strategy, positioning against SCIRP priorities, or full proposal writing support, BW&CO can:

• Align your research aims to SCIRP’s priority areas.

• Draft compelling abstracts and narratives tailored to CDMRP review criteria.

• Provide budget and compliance support based on CDMRP rules.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Agriculture and Food Research Initiative (AFRI) – Rapid Response to Weather Events Across Food & Agricultural Systems (A1712) – USDA NIFA

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The USDA National Institute of Food and Agriculture (NIFA) is awarding up to $300,000 for extension and integrated (extension + applied research) projects that address urgent impacts of recent weather-related disasters on agricultural production systems, food supply chains, and rural communities. Applications must be submitted within 45 calendar days of a qualifying weather event. Awards support 12-month rapid deployment projects.

How much funding is available?

Maximum award: $300,000 (including indirect costs). Grant duration: 12 months. Grant types: Standard and FASE (Strengthening Standard) only. Project types: Extension or Integrated (extension + applied research) only.

What could I use the funding for?

Funding supports rapid, solution-driven efforts that address impacts from naturally occurring weather hazards such as heat, drought, wildfires, tornados, floods, hurricanes, tropical storms, and blizzards.

1. Producer Stabilization & Extension Deployment

Projects that deliver rapid extension programs, technical assistance, and training to farmers, ranchers, and producers impacted by recent weather disasters.

Examples:

·        On-farm technical assistance and recovery protocols

·        Thermal stress mitigation strategies for livestock

·        Drought management tools for crop producers

·        Emergency feed or input optimization guidance

2. Tools & Technology for Rapid Adoption

Projects implementing tools and technologies that can be deployed within 90 days to mitigate disaster impacts.

·        Decision-support software for weather adaptation

·        Remote sensing or monitoring systems

·        Precision irrigation or water conservation technologies

·        Emergency disease or pest monitoring systems triggered by extreme weather

3. Supply Chain & Food System Resilience

Projects addressing disruptions across production, processing, distribution, and food safety logistics caused by weather events.

·        Alternative distribution models during disaster recovery

·        Cold chain stabilization strategies

·        Regional food access logistics

·        Processing infrastructure recovery support

4. Community & Rural Impact Mitigation

Projects supporting individuals, families, and communities to buffer disaster impacts and maintain safe, nutritious, and accessible food supplies.

·        Community resilience planning

·        Localized disaster-response communication strategies

·        Rapid recovery outreach programs

·        Food access coordination in affected regions

At least one activity must be implemented within 90 days of award, and all deliverables must be completed within 12 months.

Are there any additional benefits I would receive?

Beyond the formal funding award, there are significant indirect benefits to receiving a USDA AFRI Rapid Response award:

·        Federal validation tied to disaster resilience and food system stabilization

·        Positioning as a trusted partner for state and regional recovery efforts

·        Strengthened credibility with producers and agricultural stakeholders

·        Non-dilutive capital that extends runway during market uncertainty

·        Enhanced positioning for future USDA and federal resilience funding opportunities

What is the timeline to apply and when would I receive funding?

• Applications must be submitted within 45 calendar days of a qualifying weather event. No Letter of Intent is required. Application review and processing are expedited to ensure timely project startup. Awards have a 12-month performance period.

Where does this funding come from?

Funding comes from Congressional appropriations to the Agriculture and Food Research Initiative (AFRI) through USDA’s National Institute of Food and Agriculture (NIFA). Assistance Listing: 10.310.

Who is eligible to apply?

·        Colleges and universities

·        State Agricultural Experiment Stations

·        University research foundations

·        Federal agencies and national laboratories

·        Private organizations and corporations

·        Eligible individuals (U.S. citizens, nationals, permanent residents)

·        Consortia of eligible entities

Foreign and international organizations are not eligible as primary applicants.

What companies and projects are likely to win?

·        Projects clearly tied to a recent documented weather event

·        Strong justification of urgency and stakeholder need

·        Solutions deployable within 90 days of award

·        High likelihood of rapid adoption by producers or food system operators

·        Clearly defined geographic scope linked to the disaster impact

Are there any restrictions I should know about?

·        Budget requests exceeding $300,000 will not be reviewed.

·        Projects must focus on short-term, urgent disaster response.

·        At least one deliverable must occur within 90 days of award.

·        All projects must include a data management plan.

·        If applied research is commodity-specific and not national in scope, matching funds may be required.

How long will it take me to prepare an application?

Due to the 45-day submission window, preparation timelines are compressed. Competitive applications typically require 3–6 weeks of focused development, including event documentation, stakeholder justification, and rapid deployment planning.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Flat fee pricing available upon request.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

See the solicitation here.

CDMRP: Arthritis Research Program (ATRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Arthritis Research Program (ATRP) has released its anticipated funding opportunities for Fiscal Year 2026, funded through the Department of Defense’s FY26 Defense Appropriations Act and managed by the CDMRP. This pre-announcement is meant to help investigators prepare competitive proposals ahead of the official Funding Opportunity Announcements (FOAs).

07-22-2026 - (Pre-application - Pre-Proposal)
10-22-2026 - (Application)

How much funding would I receive?

While the total program budget for ATRP isn’t specified in the pre-announcement itself, the FY26 DoD appropriations provide funding for the ATRP as part of a broader portfolio that includes a ~$10 M allocation for arthritis research.

Per award (anticipated levels):

• Clinical Research Award

  • Research Level 1: Up to $1.3 M total costs over up to 4 years.

  • Research Level 2: Up to $3.25 M total costs over up to 4 years.

• Translational Research Award

  • Up to $800,000 total costs over up to 3 years.
    All awards count direct + indirect costs.

What could I use the funding for?

Funding is structured to support clinically relevant arthritis research:

Prevention & Early Diagnosis

• Identify factors predicting disease onset/progression

• Develop technologies or solutions for arthritis prevention.

Treatment & Burden Mitigation

• Topic 1: Evaluate interventions or strategies that alleviate pain/symptoms, improve function, address psychosocial factors, comorbidities, or pathologic disease burden.

• Topic 2: Develop new solutions targeting similar multifactorial elements of arthritis.

Translated into potential research areas:

• Pilot studies or full clinical trials (clinical research)

• Translational projects moving discoveries toward clinical application (without supporting clinical trials)

Are there any additional benefits I would receive?

• Being part of a CDMRP program provides two-tier review with both scientific and programmatic relevance evaluation (via eBRAP/Grants.gov processes).

• Opportunities to influence care and policy with clinically actionable outputs.

• Access to broader CDMRP support resources and network.

What is the timeline to apply and when would I receive funding?

07-22-2026 - (Pre-application - Pre-Proposal)
10-22-2026 - (Application)

Where does this funding come from?

Funding comes from the FY26 Defense Appropriations Act, via the Department of Defense’s Congressionally Directed Medical Research Programs (CDMRP), managed through the Defense Health Agency Research and Development Command (DHA R&D-MRDC).

Who is eligible to apply?

• Independent investigators at all academic levels or equivalents can apply for all award types.

• Clinical awards expect research aligned with program focus areas.

• Translational awards require preliminary data and aim to move findings toward clinical relevance.

What companies and projects are likely to win?

Likely competitive applicants will:

• Address prevention, early diagnosis, treatment efficacy, or multifactorial burden mitigation of arthritis.

• Show strong preliminary data, especially for translational and clinical research.

• Demonstrate clinical relevance and potential to improve patient outcomes.

• Include multidisciplinary teams with community collaborators (patients/care partners) for applicability.

Are there any restrictions I should know about?

• Pre-announcement is not a funding obligation or contract — final requirements and eligibility criteria will be defined in FOAs.

• Clinical trials require appropriate planning and justification.

• Applications for clinical research must include relevant preliminary/published data.

How long will it take me to prepare an application?

• Preparation timelines vary by mechanism:

  • Clinical Research Awards may take months to draft due to data, design, and collaborator requirements.

  • Translational Awards also require solid preliminary evidence.

  • Plan ahead for eBRAP pre-applications and revision cycles before full submission. (Recommended: map to FOA deadlines once published.)

How can BW&CO help?

BW&CO could support you by:

• Interpret the FOA once published and align your research to program priorities.

• Develop competitive research and budget narratives.

• Coordinate pre-application eBRAP submission and compliance checks.

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

CDMRP: Tick-Borne Disease Research Program (TBDRP)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Fiscal Year 2026 Tick-Borne Disease Research Program (TBDRP) pre-announcement was released by the Congressionally Directed Medical Research Programs (CDMRP) on February 12, 2026. This pre-announcement signals anticipated funding opportunities aimed at high-impact research to prevent, detect, and resolve Lyme disease and other tick-borne diseases that affect Service Members, Veterans, families, and the general public.

Pre-applications are due on 7/22/26.

Full Applications are due on 10/22/26.

How much funding would I receive?

Award-specific maximums from the pre-announcement:

• Idea Development Award – Up to $800,000 total costs over up to 3 years.

• Idea Development Award – Career Development Option – Up to $550,000 total costs over up to 3 years.

• Therapeutic/Diagnostic Research Award – Up to $1,325,000 total costs over up to 3 years.

What could I use the funding for?

Funding is intended to support innovative, high-impact research addressing tick-borne diseases. The pre-announcement defines mechanism-specific focus areas:

A) Idea Development Award

Pathogenesis

• Assess interactions among tick-borne pathogens (emphasis Lyme and co-infections)

• Study persistent clinical manifestations (neurologic symptoms encouraged)

• Studies on maternal health, pregnancy outcomes, congenital infections

Treatment

• Proof-of-concept for novel therapeutics or repurposing existing compounds

• Target identification/validation and early refinement of therapeutic candidates

Diagnosis

• Development/optimization of improved diagnostics for:

  • Single or multiple tick-borne pathogens (priority on direct detection of Borrelia burgdorferi)

  • Distinguish active Lyme infection from past exposure

  • Detect/diagnose maternal-to-fetal transmission, including relevant animal models

B) Therapeutic/Diagnostic Research Award

• Treatment – Evaluation/refinement of therapeutic candidates, including PK/PD and toxicology; designed to advance early/preclinical drug development.

• Diagnosis – Validation of novel diagnostics capable of single or multi-pathogen detection, distinguishing active from past infection, and detecting maternal-to-fetal transmission pathways.

Are there any additional benefits I would receive?

• The program explicitly supports career development options for early-career investigators (with mentorship).

• Pre-application requirements and peer review support transparency in mechanism expectations.

What is the timeline to apply and when would I receive funding?

• Pre-applications are due on 7/22/26.

• Full Applications are due on 10/22/26.

Where does this funding come from?

Funding for TBDRP is provided by the Fiscal Year 2026 Defense Appropriations Act, and administered by the Defense Health Agency Research and Development / Medical Research and Development Command (CDMRP).

Who is eligible to apply?

Eligibility varies by mechanism. From the pre-announcement:

• Independent investigators at all career levels are eligible for many mechanisms.

• Career Development Option has specific requirements:

  • PI must be within 10 years of terminal degree (with exceptions for residency/family leave)

  • Mentor must be experienced (≥5 year track record in tick-borne disease research)

What companies and projects are likely to win?

Projects that are highly innovative, directly related to the defined focus areas, and translational in nature (with clear clinical relevance) are likely to be competitive. Specifically:

• Approaches that address persistent Lyme disease, novel diagnostics, and novel therapeutic strategies

• Research that demonstrates strong rationale or preliminary data aligned with CDCMRP priorities

• Early-career investigators partnered with experienced mentors (for Career Development Option)

Are there any restrictions I should know about?

• Clinical trials cannot be supported under these mechanisms; human studies are permitted where applicable.

• Full application submission is by invitation only after pre-proposal review.

• Mechanism‐specific eligibility and focus area alignment are strict and will be enforced in the FOA.

How long will it take me to prepare an application?

Preparation time varies significantly by mechanism and institutional support, but given the requirement for pre-proposals, preliminary data, and alignment with specific focus areas, investigators should plan for 6–12 weeks of preparation once the FOA is released. This accounts for drafting, internal review, and compliance checks prior to pre-application submission.

How can BW&CO help?

BW&CO can help you:

• Interpret and map your research to specific TBDRP focus areas

• Develop pre-proposal drafts and strategic research narratives

• Identify data needs and plan for compliant application packages

• Coordinate mentor relationships for career development submissions

• Set milestones to meet pre-application and full application deadlines

How much would BW&CO Charge?

We have both fractional engagements ($250 an hour) and full engagements ($13,000 + 5%) available.

Additional Resources

Review the solicitation here.

Development of Radiological/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices

Updated October 2026: NIAID released RFA-AI-27-014, which covers radiation medical countermeasures and biodosimetry (Research Areas 1 to 3). Applications are due November 9, 2026, with later due dates on October 8, 2027 and October 9, 2028.

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The National Institute of Allergy and Infectious Diseases (NIAID) is actively seeking proposals to develop radiological/nuclear medical countermeasures (MCMs) or biodosimetry biomarkers and devices to support response to a radiological or nuclear public health emergency. This is a cost-reimbursement contract opportunity, not a grant, and is intended to advance technologies that reduce mortality, guide triage, and improve treatment decisions after radiation exposure. Proposals are due May 4th, 2026.

How much funding would I receive?

• Total contract value: Not specified (listed as “TBD” in the solicitation)

• Contract type: Cost-reimbursement with fixed fee

• Base period funding: TBD

• Option periods: Up to two option periods, funding TBD

Because dollar amounts are not pre-set, funding levels will depend on scope, cost realism, and negotiation with NIAID.

What could I use the funding for?

Funding must support one of the two objectives below.

A. Radiological/Nuclear Medical Countermeasures (MCMs)

Funding may be used to develop safe and effective MCMs that:

• Mitigate and/or treat normal tissue injuries caused by ionizing radiation

• Reduce radiation-associated mortality or major morbidities

• Are efficacious 24 hours or later post-exposure (MCMs intended for immediate post-exposure use are generally excluded, unless otherwise noted in the objectives)

B. Biodosimetry Biomarkers and Devices

Funding may be used to advance biodosimetry biomarkers and/or devices that:

• Inform triage and treatment strategies

• Are suitable for use during a radiation public health emergency

Allowable Cost Categories (with Contracting Officer approval where required) include:

• Personnel and research labor

• Subcontracts and consultants

• Travel (including foreign travel)

• Patient care costs

• Equipment and materials

• Printing and reporting

• Research-related conferences and meetings

Are there any additional benefits I would receive?

In addition to funding, awardees receive:

• A direct contractual relationship with NIH/NIAID

• Eligibility for option period extensions at the government’s discretion

• The ability to generate patents, subject to federal invention regulations

• Increased credibility for future BARDA, NIH, and DoD opportunities

What is the timeline to apply and when would I receive funding?

• Solicitation issued: February 10, 2026

• Questions due: March 3, 2026 (recommended)

• Proposal deadline: May 4, 2026 at 3:00 PM ET

• Contract period of performance: TBD

• Funding start: After award and contract execution (date not specified)on maturity or need

Where does this funding come from?

This funding is provided by the National Institute of Allergy and Infectious Diseases (NIAID) within the National Institutes of Health (NIH), U.S. Department of Health and Human Services.

Who is eligible to apply?

Eligible applicants include:

• For-profit companies

• Small businesses

• Nonprofits and research institutions

• Universities

• Domestic and foreign entities

Applicants must be registered in SAM prior to award.

What companies and projects are likely to win?

NIAID is looking for teams that:

• Have strong scientific and technical rationale

• Address clearly defined unmet needs in radiation response

• Can demonstrate feasible development and execution plans

• Align tightly with the Research and Technical Objectives in the solicitation

Projects are evaluated primarily on technical merit, relevance to agency priorities, and availability of funds.

Are there any restrictions I should know about?

Key restrictions include:

• You may only submit one focus per proposal (MCM or biodosimetry)

• Certain costs require prior Contracting Officer approval

• Strict compliance with human subjects, animal welfare, data sharing, and publication policies

• Funds may not be used for prohibited activities (e.g., abortion, human embryo research, needle exchange, promotion of controlled substances legalization)

How long will it take me to prepare an application?

Most companies should plan for 8–12+ weeks to prepare:

• A full technical proposal and Statement of Work

• A detailed cost proposal and supporting documentation

• Required representations, certifications, and attachments

How can BW&CO help?

BW&CO can:

• Translate the BAA into a clear win strategy

• Define scope, milestones, and budget that survive NIH negotiation

• Draft or review the technical and business proposals

• Ensure compliance with NIH contract requirements

• Position your company for option periods and follow-on funding

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

Air Force Cryptologic Office (AFCO) Commercial Solutions Opening (CSO)

Updated October 2026: A September 30, 2026 update extended the AFCO CSO (FA7037-21-S-C001) through September 30, 2027.

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Air Force Cryptologic Office (AFCO) is actively seeking innovative commercial technologies to support U.S. Air Force cyberspace intelligence, electromagnetic warfare, information operations, and multi-domain operations. This Commercial Solutions Opening (CSO) is designed to move fast, fund mature technologies applied in novel ways, and support field demonstrations—ideally within one year.

How much funding would I receive?

AFCO expects to make individual awards ranging from:

• $50,000 to $50,000,000 over the full period of performance

These amounts are not strict limits. Proposals over $15,000,000 must include phased options that allow for incremental funding. All awards are subject to the availability of funds.

What could I use the funding for?

Funding may be used to develop, demonstrate, test, or deploy innovative commercial technologies aligned with AFCO’s mission areas. Proposals must address one or more of the following capability areas:

AFCO-CM-001, ELECTROMAGNETIC WARFARE (EW)

• Electromagnetic attack, support, and protection

• EW data fusion and advanced signal processing

• Cognitive EW and AI/ML-enabled techniques

• EW battle management and waveform generation

AFCO-CM-002, INFORMATION OPERATIONS (IO)

• Technologies that affect adversary decision-making

• Capabilities targeting informational, physical, or cognitive dimensions

• Generative AI or autonomous AI applied to the information environment

AFCO-CM-003, Electromagnetic Digital Communications

• Free-space and space-based digital communications

• Access, denial, disruption, degradation, deception, or destruction of communications

• Novel approaches emphasizing extensibility over single-purpose solutions

AFCO-CM-004, Multi-Domain Innovation

• Integrated effects across EW, cyberspace, ISR, and information operations

• Automated and synchronized multi-domain operational capabilities

Are there any additional benefits I would receive?

In addition to funding, successful companies may receive:

• Direct engagement with Air Force technical and operational stakeholders

• Opportunities for follow-on contracts or Other Transactions (OTs)

• Potential multi-year periods of performance (up to five years)

• A clear pathway from prototype to operational relevancest Proposal and SOW).

What is the timeline to apply and when would I receive funding?

• Phase I: Quad Chart and White Paper may be submitted at any time before September 30, 2026

• Phase II: Only by invitation from the Contracting Officer

• Proposal preparation window (Phase II): 30 calendar days from invitation

• Expected contract start: Approximately 90 days after proposal submission

Period of performance:

• Typically 1–5 years, with exceptions considered based on maturity or need

Where does this funding come from?

Funding is provided by the Air Force Cryptologic Office (AFCO), Cyberspace ISR and Multi-Domain Innovation Division, under the U.S. Department of the Air Force.

Awards may be issued as:

• Firm Fixed Price (FFP) contracts

• Fixed Price Incentive (FPI) contracts

• Other Transactions (OTs) under 10 U.S.C. §2371bal Medicines).

Who is eligible to apply?

Eligible applicants include:

• U.S.-based commercial companies

• Small businesses and non-traditional defense contractors

• Companies offering commercial items, technologies, or services

To receive an award, companies must:

• Be registered in SAM.gov

• Be considered responsible under FAR Part 9.1

• Meet any security clearance requirements if proposing classified work

What companies and projects are likely to win?

Successful proposals typically:

• Apply mature technologies in novel ways

• Demonstrate clear relevance to AFCO mission needs

• Support field demonstrations within one year (ideally)

• Offer measurable improvements to operational effectiveness

• Align with open architecture approaches (e.g., SOSA, OMS/UCI, modular software/hardware)

Are there any restrictions I should know about?

Yes. Key restrictions include:

• All submissions must be commercial solutions

• Classified submissions require prior coordination

• Proposals exceeding page limits will not be evaluated

• Intellectual property assertions must follow DFARS requirements

• AFCO may partially fund, incrementally fund, or decline any proposal

How long will it take me to prepare an application?

Typical preparation times:

• Phase I (Quad Chart + White Paper): 1–3 weeks

• Phase II (if invited): 30 calendar days

The Phase II submission includes a technical proposal, statement of work, and detailed pricing.

How can BW&CO help?

BW&CO can help you:

• Rapidly assess fit against AFCO’s priority areas

• Shape your Quad Chart and White Paper for evaluator clarity

• Position your technology for Phase II invitation

• Translate technical capabilities into mission-aligned value propositions

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

National Defense Stockpile (NDS) Research & Qualification BAA – DLA

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Defense Logistics Agency (DLA) Strategic Materials office is seeking white papers under its National Defense Stockpile (NDS) Research and Qualification Broad Agency Announcement to fund research, development, and qualification of strategic and critical materials that strengthen domestic supply chains. Awards may support early-stage research through higher-TRL qualification efforts, with individual awards up to $10 million. The BAA is open from January 30, 2026 through January 30, 2029, with white papers due no later than May 1, 2028.

How much funding would I receive?

Individual awards are expected to range from relatively small research efforts up to $10,000,000 per award, with multiple smaller awards more likely than a single large award. Phase I efforts are limited to the Simplified Acquisition Threshold ($250K) and up to 12 months, while Phase II efforts may be funded for up to $10 million with periods of performance up to 24 months.

What could I use the funding for?

Funding may be used for research, development, demonstration, and qualification activities related to strategic and critical materials according to the following priorities:

Priority 1: Antimony, Bismuth, Gallium, Germanium, REEs and REE Magnet Materials

Priority 2: Graphite, Battery Materials, Magnesium, Refractory Metals, Energetics

Priority 3: ZOC and Related Materials, Indium, PGMs, Neon, Manganese

Priority 4: High Purity Aluminum, Beryllium, Cobalt, Scandium and Yttrium, Fluorspar


Areas of interest for the above materials are:

(1) Refining, Processing, and Beneficiation:

The research of, assessment of, evaluation of, development of, demonstration of, or establishment of:

(a) Processes to enhance the quality of materials, improve efficiency of production processes, refine or benefit from material, or mitigate recurring problems.

(b) Impacts of and solutions to external “bottlenecks” in raw material supply chains addressing materials that have been delayed, duration of the shortages, effect on production lead times, prices and impact on delivery of finished products.

(c) Impacts of and solutions to internal “bottlenecks” in materials refining processes related to converting feedstock into sellable product considering issues such as incorrect or inferior feedstock, equipment failures, lack of skilled work forces, etc.

(2) Recycling, Conservation and Substitution Options:

Identification of, evaluation of, developing methods for, and establishing domestic capabilities to:

(a) Material substitutes in active use by domestic and trade-friendly international processors and manufacturers; include limitations and common issues associated with use of the substitute material.

(b) Research to develop or qualify materials as acceptable substitutes including use of existing and emerging products.

(c) Recycling opportunities, including industrial infrastructure and logistical perceived limitations.

(d) Recycle and recover neodymium iron boron (NdFeB) or Samarium Cobalt (SmCo) magnets or recovery of rare earths or its alloys. The specifications should include the total rare earth metals (TREM) present in the recycled magnets. As well as identification of energy magnetic density of the recycled magnets.

(3) Qualification of Materials:

(a) Qualification of Research to Department of Defense Programs of Record. Projects will require letters of support from known DOD Programs of Record indicating intent to utilize the qualified material upon successful completion of the work.

Are there any additional benefits I would receive?

Beyond the formal contract award, there are meaningful indirect benefits to receiving a DLA Strategic Materials award:

• Government Validation and Credibility: Selection signals technical merit and relevance to U.S. defense supply-chain priorities.

• Stronger Position in Defense Supply Chains: Successful projects can lead to qualification for DoD Programs of Record, unlocking long-term procurement opportunities.

• Nondilutive Technology Advancement: Companies can mature materials and processes without equity dilution.

• Improved Exit and Acquisition Potential: Government-validated materials qualification can increase strategic value to primes and acquirers.

What is the timeline to apply and when would I receive funding?

The BAA is open from January 30, 2026 through January 30, 2029. White papers may be submitted on a rolling basis but must be received by May 1, 2028. White papers are evaluated as received, and selected offerors may be invited to submit full proposals. All evaluations cease on August 1, 2028, and awards must be made by September 15, 2028.

Where does this funding come from?

Funding is provided by the Defense Logistics Agency (DLA) Strategic Materials program under its authority to support the National Defense Stockpile and strengthen domestic strategic and critical materials supply chains.

Who is eligible to apply?

Any responsible domestic source capable of performing the required research may submit a white paper. Eligibility includes businesses, nonprofits, and educational institutions that are registered in SAM.gov. Foreign-owned firms may participate subject to foreign disclosure review. There is no set-aside for small businesses, though small and disadvantaged businesses are encouraged to participate.

What companies and projects are likely to win?

Successful proposals typically demonstrate:

• Strong scientific and technical merit that improves strategic materials supply-chain resilience

• Clear alignment with one or more stated Areas of Interest and listed strategic materials

• Innovative, feasible, and non-duplicative technical approaches

• Qualified teams with relevant facilities, experience, and past performance

• Reasonable and realistic pricing supported by deliverables

Are there any restrictions I should know about?

White papers must be unclassified and may not contain proprietary information. A white paper submission is mandatory to be eligible for a full proposal. Projects are limited to a maximum of three years, depending on phase.

How long will it take me to prepare an application?

For first time applicants, white-papers will likely take 35 to 50 hours without BW&CO assistance.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

Installation Energy & Water - Environmental Security Technology Certification Program (ESTCP)

Updated October 2026: ESTCP posted a new Open Topics BAA (W912HQ26S0051) on August 21, 2026 that includes Installation Energy and Water. White papers are accepted through August 20, 2027.

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Environmental Security Technology Certification Program (ESTCP) is soliciting pre-proposals for FY 2027 to fund formal demonstrations of innovative Installation Energy & Water technologies. ESTCP supports mature technologies that improve energy resilience, water resilience, cybersecurity, and building performance at DoD installations through real-world demonstrations conducted at DoD facilities. Pre-proposals are due March 26, 2026 at 2:00 p.m. ET.

How much funding would I receive?

ESTCP awards typically support multi-year demonstration projects funded through cost-type or firm fixed-price contracts. While individual award sizes are not specified in the solicitation, projects commonly range from hundreds of thousands to several million dollars, depending on scope, duration, and demonstration scale.

What could I use the funding for?

Funding may be used to demonstrate and validate innovative technologies in one of the following ESTCP FY 2027 Installation Energy & Water Topic Areas:

Improve Energy Resilience with Long-Duration Energy Storage
This topic area seeks demonstrations of Long Duration Energy Storage (LDES) technologies integrated into military microgrids to meet the DoD’s requirement to power critical loads for 14 days during a grid outage. Technologies of interest include electrochemical, chemical, thermal, subsurface, and other LDES approaches, evaluated through Hardware-in-the-Loop (HIL) testing. The focus is on reducing or eliminating reliance on diesel fuel while improving lifecycle cost-effectiveness, resilience, and cybersecurity of installation microgrids.
Read more here.

Improving the Cyber Resilience of DoW Installation Energy Systems
This topic focuses on closing critical cybersecurity gaps in Facility-Related Control Systems (FRCS) that support energy and water infrastructure. ESTCP is seeking demonstrations of novel solutions that improve secure connectivity, threat detection, and cyber defense at machine speed, including alternatives to fiber connectivity, high-fidelity honeypots, and AI-driven defensive cyber agents. The goal is to reduce the risk of cyber-physical disruption to mission-critical installation systems without requiring major infrastructure modifications.
Read more here.

Improving the Energy Resilience of DoW Installations
This topic area solicits technologies that enhance the ability of military installations to continue mission-critical operations during energy disruptions. Solutions may include hardware, software, planning tools, infrastructure hardening, or integrated energy-water-control approaches, but exclude LDES-only solutions, which must submit under the LDES topic. Technologies should reduce dependence on imported energy, address regional challenges (e.g., arctic, remote, or arid locations), and demonstrate scalability across multiple installations.
Read more here.

Solutions to Improve Energy Efficiency and Performance of DoW Buildings
This topic seeks demonstrations of innovative retrofit-ready technologies that reduce energy use intensity, lower maintenance burden, improve occupant health, and decrease lifecycle costs in DoD buildings. Technologies of interest include HVAC, building envelope systems, lighting, water heating, waste heat recovery, and integrated control solutions. ESTCP prioritizes solutions that work with existing infrastructure, deliver measurable energy savings, and have a clear pathway to adoption through ESCOs, ESPCs, or utility programs.
Read more here.

Water Resilience on DoW Installations
This topic area focuses on technologies and methodologies that improve the reliability, security, and efficiency of water systems supporting military missions. Areas of interest include potable water reduction, water storage (minimum 8,000 gallons), desalination improvements, leak detection, corrosion-resistant materials, building-scale water reuse, and advanced water monitoring. Solutions should reduce operational burden, address water-stressed regions, and support long-term resilience of aging installation water infrastructure.
Read more here.

Are there any additional benefits I would receive?

Beyond the direct funding award, ESTCP provides significant strategic advantages:

• DoD Validation and Credibility: ESTCP selection signals that your technology meets high-priority DoD installation needs and has passed rigorous technical review.

• Accelerated Adoption Pathways: Demonstrations are explicitly designed to support transition, regulatory acceptance, and scaling across multiple DoD installations.

• Non-Dilutive Growth: ESTCP funding allows companies to mature and validate technology without giving up equity, strengthening long-term enterprise value.

• Visibility with Defense Stakeholders: Successful projects are published, presented, and shared across DoD, regulatory, and industry communities—raising profile and credibility.

What is the timeline to apply and when would I receive funding?

• Pre-Proposals Due: March 26, 2026 (2:00 p.m. ET)

• Full Proposal Invitations: May 2026

• Full Proposals Due: July 2026

• Technical Committee Briefings: August 2026

• Project Selection: September 2026

• Anticipated Contract Awards: Q3 FY 2027.

Where does this funding come from?

Funding is provided by the Environmental Security Technology Certification Program (ESTCP) under the Office of the Deputy Assistant Secretary of Defense (Energy Resilience & Optimization) within the U.S. Department of Defense.

Who is eligible to apply?

Eligibility depends on organization type:

• Private industry and universities: Apply under the FY27 ESTCP Broad Agency Announcement (BAA)

• DoD organizations: Apply under the FY27 DoD Call for Proposals

• Other Federal agencies: Apply under the FY27 Federal Call for Proposals

All proposers must submit a pre-proposal and respond to an eligible Topic Area.

What companies and projects are likely to win?

Successful proposals typically:

• Address a clearly defined, enterprise-wide DoD installation need

• Demonstrate technologies at TRL or ARL 5–7

• Provide strong cost, performance, and risk-reduction benefits

• Include a clear DoD end user and transition pathway

• Are scalable across multiple installations and Services

Are there any restrictions I should know about?

Projects will not be considered responsive if they:

• Are already broadly deployed across the DoD enterprise

• Require access to large volumes of high-quality DoD data

• Solve a problem unique to a single installation

• Represent basic research or early-stage exploratory development

How long will it take me to prepare an application?

For first time applicants, pre-proposals will likely take 35 to 50 hours with assistance.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

MassVentures START (SBIR TARgeted Technologies) Program Round 1 Grants

Updated October 2026: MassVentures says the START application window will reopen on February 1, 2027.

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

MassVentures’ START program provides non-dilutive grants to help Massachusetts companies that have already won a federal Phase II SBIR or STTR award (or equivalent) move toward commercialization. The program’s stated goals include commercialization, job growth, manufacturing expansion, and statewide innovation.

Who should apply?

1. You are a Massachusetts company that conducts R&D, manufacturing, and commercialization primarily in MA, and is committed to continuing to do so.

2. You have received a federal Phase II SBIR or STTR award (or equivalent).

3. You expect to spend START funds primarily in Massachusetts.

Timing note: There is no strict requirement on when your qualifying Phase II was received. If it was more than five years ago, you’re expected to explain why it’s still commercially relevant today.

Funding snapshot:

16 winners will receive $100k in Round 1 in 2026 (paid in two installments). Round 1 winners will be eligible to compete for 7 Round 2 awards in 2027 for $200k. Round 3 is finally for $500k for 3 awardees.

Key dates:

• Application deadline: Monday, February 23, 2026 — 11:59 PM ET

• Top 16 selected - March 23, 2026

• Winners Notified - April 30th, 2026

• Winner’s breakfast - May/June

What you must submit:

1. 2026 Application Cover Sheet (contact information)

2. 1000-word summary covering: the technology, its commercial potential, and the team

3. 3-minute video

4. Cover page of your SBIR Phase II award contract (proof of award)

How applications are evaluated:

This RFP references learning “what makes a successful application” and “what judges look for” during the info session, but it does not list formal scoring criteria in the text provided.
What is explicitly required in the application suggests emphasis on:

• Clear explanation of the technology

• Credible commercial potential

• Strength of the team

Practical guidance for CEOs

1. Treat the 1000-word summary as your “investment memo”: what it is, why it wins, how it becomes a business.

2. Use the 3-minute video to make the story memorable and concrete: problem → solution → proof → market → plan.

3. If your Phase II is older than 5 years, be direct about why it still matters commercially now.

How can BW&CO help?

BW&CO helps founders and CEOs decide quickly whether this opportunity is worth pursuing and how to win it. We translate the START RFP into plain-English strategy, pressure-test fit and competitiveness, shape a clear commercialization narrative for the 1,000-word summary and 3-minute video, and manage the application end-to-end so your team stays focused on building the business. Our goal is to reduce time burden, avoid preventable mistakes, and submit a credible, CEO-ready application aligned with what MassVentures is explicitly asking for.

How much would BW&CO Charge?

With a flat rate of $2500, you’d work with our grant writing team to put the application together and submit before the February 23rd deadline.

Additional Resources

Review the solicitation here.

Project WILLFUL – Next Generation Specialist Vehicles – Cyber & Specialist Operations Command (CSOC)

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

Project WILLFUL is a long-term UK Ministry of Defence R&D and experimentation initiative led by Cyber & Specialist Operations Command (CSOC) to inform a parallel land manoeuvre programme over the next 10–15 years. US Companies are eligible to apply. Through Collaborative Working Innovation Contracts (CWICs, the UK analogue to a CRADA), CSOC will collaborate directly with industry to mature and demonstrate novel technologies on a light, high-mobility 4x4 specialist vehicle platform. Submissions are accepted via Scout Cards until 01 January 2027.

How much funding would I receive?

Est. $500K to $5 million. Funding is expected to be provided through CWICs and related collaborative R&D and capability demonstration activities over the lifetime of the project.

What could I use the funding for?

Funding and collaboration under Project WILLFUL may be used to research, develop, integrate, and demonstrate novel technologies aligned to the following Technology Interest Items:

Alternative Powertrains. Realising the benefits of electric motors at the axels or wheel stations without sacrificing the requirement to run on traditional and dirty fuels. Novel hybrid solutions that are optimised for performance, not emissions. Reduce training, cognitive load on the operator and maintenance. Afford 'silent' approach (reduced audio and thermal signature). Increase exportable power for sub-systems. Future proof for the point where pure EV becomes viable. Improve torque characteristics.

Increasing Payload. Powered Trailers. UGVs. Modified third axles. Novel chassis construction.

C-UAS. Hard and soft kill.

Signature Management. Either through physical profile, such as additive manufacturing solutions or modifiable body kits. Or mounted reductive systems for thermal, audio, IR, EM, RF and counter MLM-enabled object recognition.

Exportable Power. Generation and distribution. Power harvesting.

Protection. Modular ballistic protection. Modular blast protection. Soft kill DAS.

Low profile and light weight Remote Weapons Station. Specifically, options that can be either fitted or removed quickly without specialist tools or can be hidden within vehicle architecture and brought to bear when needed.

Are there any additional benefits I would receive?

Beyond direct R&D collaboration, participation in Project WILLFUL offers significant indirect benefits. Working directly with CSOC and specialist end users provides early insight into future UK land manoeuvre requirements and long-term capability direction. Successful contributors gain credibility through direct Ministry of Defence collaboration, access to spiral acquisition pathways over a 10–15 year horizon, and positioning for follow-on programmes as requirements mature. The use of CWICs enables deeper technical collaboration than traditional procurement mechanisms.

What is the timeline to apply and when would I receive funding?

Vendors are encouraged to submit Scout Cards as early as possible, as engagement, experimentation opportunities, and CWIC pathways may be pursued on a rolling basis as funds and collaboration slots are allocated. Early submissions are more likely to influence ongoing research, experimentation, and requirement-setting activities.

The Scout Card submission window opened on 26 January 2026 at 18:00 CST and formally closes on 01 January 2027 at 17:59 CST. Project WILLFUL is expected to continue throughout the full spiral delivery of the associated land manoeuvre programme over 10–15 years, with capability interest areas and CWICs reviewed periodically.

Where does this funding come from?

Funding and collaboration are provided by the United Kingdom Ministry of Defence, delivered through Cyber & Specialist Operations Command (CSOC) using procurement reform mechanisms and Collaborative Working Innovation Contracts (CWICs).

Who is eligible to apply?

There is no initial threshold requirement for vendors at first consideration. However, to proceed beyond initial review and toward CWIC award, vendors will be required to share information at UK SECRET. Security accreditation may inform down-selection.

As a baseline, vendors should seek to secure:

• Facility Security Clearance

• Suitable personnel security clearances (UK SECRET or equivalent)

• United Kingdom Security Vetting (GOV.UK clearance levels)

What companies and projects are likely to win?

Projects most likely to succeed are those that:

• Demonstrate novel technologies aligned to the listed Technology Interest Items

• Can integrate solutions onto a light, high-mobility 4x4 military-spec platform

• Support rapid experimentation, spiral development, and evolving requirements

Are there any restrictions I should know about?

Subsequent participation beyond initial consideration will require the ability to handle information classified at UK SECRET. Security accreditation and vetting may restrict participation for vendors unable to meet these requirements.

How long will it take me to prepare an application?

Initial participation requires submission of a Scout Card. For a first time applicant this will take 20-40 hours to submit without assistance from BW&CO.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 for the Scout Card Submission.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.

Science & Technology Long Range Broad Agency Announcement (LRBAA 24-01) – Department of Homeland Security

Below is a brief summary. Please check the full solicitation before applying (link in resources section).

Executive Summary:

The Department of Homeland Security (DHS) Science and Technology Directorate (S&T) is funding scientific and technical research projects that significantly improve or increase capabilities across the Homeland Security Enterprise. This Long Range Broad Agency Announcement (LRBAA 24-01) supports near-term operational needs, foundational science, and future/emerging threat research through contracts, grants, cooperative agreements, and Other Transaction Agreements (OTAs). Apply before funds are fully utilized.

How much funding would I receive?

Est. $500K to $5 million. The LRBAA does not specify minimum or maximum award sizes. Funding amounts depend on the technical merit of the proposal, relevance to DHS mission needs, and availability of funds. DHS may fund all, some, or none of the proposals received, and multiple awards are anticipated

What could I use the funding for?

Funding under this LRBAA may be used for research, development, test, and evaluation (RDT&E) activities aligned with DHS Science & Technology Directorate mission needs. DHS is currently seeking projects across the following priority research topic areas. See full topic descriptions here.

Counter Terrorism and Homeland Security Threats (CTHOM)
DHS S&T works to identify individuals or groups that intend to conduct terrorist attacks and/or illicitly move weapons, dangerous goods, and contraband. It also provides assessments of high-consequence attack methods such as CBE threats that terrorists may use to attack the United States.

CTHOM 01: Development of Tools for Test and Evaluation of Machine Learning Algorithms
DHS S&T seeks development of cost-effective methodologies and tools for training and testing of Machine Learning-based (ML-based) algorithms for detecting explosives and contraband in Computed Tomography (CT) and Millimeter Wave (MMW) images. This includes methods to synthesize training and testing data, methods to perturb empirical data in order to explore and explain algorithm performance characteristics, and tools to assess the completeness and diversity of training and test data sets.

CTHOM 03: Novel Approaches and Locations for Explosive Performance Characterization and Testing
Enabling research for the characterization and testing of explosives poses a unique challenge for threat characterization. Innovative tools and methods are needed to provide improvements in evaluating legacy approaches to characterization, adapting state-of-the-art technologies in related disciplines, and integrating emerging innovations.

Secure U.S. Borders and Approaches (BORAP)
DHS secures U.S. borders, territorial waters, ports, terminals, waterways, and air, land, and sea transportation systems. DHS S&T invests in border security research and development for technologies and solutions to prevent illicit movement and the illegal entry or exit of people, weapons, dangerous goods, and contraband.

BORAP 01: Screening at Speed
Screening at Speed seeks to mature transformative technologies that increase aviation security effectiveness from curb-to-gate while dramatically reducing wait times and improving passenger experiences.

BORAP 04: Countering Unmanned Aircraft Systems
The primary objective of this LRBAA is to develop enhanced technologies and methods that allow for the detection, tracking, identification, and mitigation of unmanned aircraft systems under varied terrains and environmental conditions such as dense urban environments, mass gatherings, critical infrastructure, mobile platforms, and remote terrain.

BORAP 07: Detection Canine Technologies
Detection Canine development interests are focused on canine research and development structure and function, development and testing of canine training aids, and independent operational test and evaluation to advance detection canine performance in operational environments.

Secure Cyberspace and Critical Infrastructure (CYBCI)
Protecting individuals and organizations from cyber attacks requires RDT&E, test and evaluation, and the technology transition of advanced cybersecurity and information assurance solutions to secure current and future critical cyber infrastructure.

CYBCI 02: Shared Cyber Resilience
The research and development of improved models of resilience across networked hardware and software systems and organizations, including automated cyber attack mitigation, resilient machine learning approaches, privacy preservation techniques, secure multi-party computing, and human-machine teaming for cybersecurity.

CYBCI 03: Software and Hardware Supply Chain Assurance
The research and development of tools and techniques to ensure the resilience of the data, software, and hardware used to execute homeland security mission functions, including post-quantum cryptography, secure-by-design architectures, microelectronics, IoT, cloud and edge computing, and DevSecOps supply-chain assurance techniques.

CYBCI 04: Trustworthy and Responsible Artificial Intelligence
Research and development to enable DHS to effectively assess AI/ML systems against technical and mission metrics, provide operators an appropriate level of trust and confidence, and inspire trust in the general public toward AI/ML systems deployed by DHS.

CYBCI 05: Advanced and Emerging Data Computation and Analytics
This topic focuses on novel computational and analytic methods and capabilities for large-scale data sets for DHS missions, including real-time analytics, privacy-enhancing technologies, high-performance computing, digital twins, synthetic data, and advanced analytics to improve mission effectiveness and efficiency.

Are there any additional benefits I would receive?

Beyond the direct funding, LRBAA awards provide several indirect advantages:

• Government Validation and Credibility: Selection signals strong technical merit and alignment with DHS mission priorities.

• Pathway to Transition and Deployment: Projects are designed to support operational relevance and transition to DHS components.

• Access to DHS Test and Evaluation Infrastructure: DHS may provide access to government laboratories and operational test facilities where appropriate.

• Stronger Long-Term Commercial and Contracting Potential: DHS-funded R&D can increase credibility with future government customers and partners.

What is the timeline to apply and when would I receive funding?

This LRBAA is open through May 31, 2029 at 11:59 PM ET. Companies should apply as soon as possible while funds are available. Submissions follow a three-step process:

1. Industry Engagement Submission (initial research concept)

2. Virtual Pitch (by invitation only)

3. Written Proposal (by invitation only)

Typical DHS response timelines (subject to change):

• Industry Engagement feedback: ~10 business days

• Virtual Pitch evaluation: ~21 business days

• Written Proposal evaluation: ~21 business days

Award timing depends on evaluation outcomes and funding availability.

Where does this funding come from?

Funding is provided by the Department of Homeland Security Science and Technology Directorate (DHS S&T) through the Office of Procurement Operations.

Who is eligible to apply?

Eligible applicants include:

• U.S. small businesses and large businesses

• Academic institutions

• Government laboratories and Federally Funded Research and Development Centers (FFRDCs)

• Nonprofits and research organizations

Foreign or foreign-owned entities may participate but are subject to export control, foreign disclosure, and other federal review requirements. There are no set-asides, but DHS strongly encourages small business participation.

What companies and projects are likely to win?

Proposals are evaluated based on:

• Alignment with DHS mission needs and topic relevance

• Scientific and technical merit of the proposed approach

• Degree of innovation and potential capability improvement

• Operational relevance and transition potential

• Reasonableness of cost and feasibility of execution

Are there any restrictions I should know about?

Key restrictions include:

• Proposal preparation costs are not reimbursable

• Only unclassified materials may be submitted

• Mature commercial products and support services are not eligible

• Participation in later proposal stages is invitation-only

• Export control, IP, and data rights requirements apply

How long will it take me to prepare an application?

Without BW&CO’s assistance the Industry Engagement submission would typically take 35-50 hours.

How can BW&CO help?

Our team specializes in complex federal R&D proposals and can:

• Triple your likelihood of success through proven strategy and insider-aligned proposal development

• Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations

• Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth under Federal & State R&D Initiatives.

How much would BW&CO Charge?

Our full service support is available for a flat fee of $4,000 for the Industry Engagement Submission.

Fractional support is $300 per hour.

For startups, we offer a discounted rate of $250 per hour to make top-tier grant consulting more accessible while maintaining the same level of strategic guidance and proposal quality.

Additional Resources

Review the solicitation here.